Лучевая терапия в комбинированном лечении немелкоклеточного рака легкого. Объемы облучения, фракционирования дозы
Аннотация
Рак легкого является наиболее часто диагностируемым онкологическим заболеванием в мире и основной причиной смертности, ежегодно приводя к более чем 1,6 миллионам смертей [14]. Восемьдесят пять процентов диагнозов приходятся на немелкоклеточный рак легкого. Роль лучевой терапии наиболее эффективно зарекомендовала себя при местнораспространенном процессе и на ранней стадии немелкоклеточного рака легкого. В этом обзоре будет обсуждаться текущее состояние современной лучевой терапии для немелкоклеточного рака легкого, ограничения и стратегии для улучшения клинических результатов в будущем.
Литература
1. Аникеева О.Ю. Сравнение стереотаксических методик облучения начальных стадий немелкоклеточного рака легкого у пожилых пациентов/ О.Ю. Аникеева, К.С. Тевс, О.А. Пашковская, Е.А. Самойлова// Российский онкологический журнал.2014. No1–С.13–19.
2. Арсеньев А.И., Канаев С.В., Новиков С.Н., Барчук А.А., Антипов Ф.Е. Современные тенденции использования лучевой терапии в лечении местнораспространенных (IIIA / N2 стадия) и ранних форм (I–II стадия) немелкоклеточного рака легкого, или роль лучевой терапии в лечении немелкоклеточного рака легкого на современном этапе. Злокачественные опухоли. 2017;(3s1):26-34.
3. Вальков М. Ю., Скрипач Ю. В., Соловьева Е. П. с соавт. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ.//Вестник РНЦРР. -2014. -№ 9. -стр. 9.
4. Гоголин Д., Гулидов И., Рагулин Ю. Лучевая терапия в лечении немелкоклеточного рака легкого Врач. 2016.-N 2.-С.46-48
5. Климанов М.Ю., Сивак Л.А., Тарасенко Т.E., Аскольский А.В., Майданевич Н.Н., Лялькин С.А., Веревкина Н.О. Современные подходы к лечению пациентов с неоперабельным немелкоклеточным раком легкого// Национальный институт рака, Киев
6. Лучевая терапия заболеваний органов грудной клетки. Лучевая диагностика органов грудной клетки/ Т. Р.Алексеева, А.И.Шехтер, В.Н.Троян, О.Ю.Аникеева// Национальное руководство.–М.: ГЭОТАР-Медиа, 2014. –Гл. 2
7. АникееваО.Ю. Алгоритм выбора методики облучения у больных раком легкого с сердечно-сосудистой патологией/О.Ю. Аникеева, Е.В. Кижаев, П. В. Филатов, О.А. Пашковская//Российский электронный журнал лучевой диагностики (REJR). –2015.–Т. 5. –No 4.С 74-82
8. Мартынова Н.И. , Воробьев Н.А. , Михайлов А.В. , Смирнова Е.В. , Гуцало Ю.В. Применение стереотаксической лучевой терапии у пациентов с первичными и метастатическими опухолями легких. Регулярные выпуски «РМЖ» №16 от 07.09.2017 стр. 1169-1172
9. Соловьева Е.П.Факторы эффективности лечения неоперабельного немелкоклеточного рака легкого III стадии// Сибирский онкологический журнал.2016.-№4.-С.39-44
10. Солодкий В.А., Сотников В.М., Паньшин Г.А., Троценко С.Д., Харченко В.П., Чхиквадзе В.Д., Нуднов Н.В., Моргунов А.А. Роль современных технологий послеоперационной лучевой терапии в комбинированном лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2017.-№3. С. 28-32
11. Троценко С. Д., Солодкий В. А., Сотников В. М. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость.//Вопросы онкологии. -2015. -Т. 61. -№ 1. -С. 71-76
12. Троценко Сергей Дмитриевич. Послеоперационная лучевая терапия немелкоклеточного рака легкого в режиме среднего фракционирования: диссертация ... кандидата Медицинских наук: 14.01.13 / Троценко Сергей Дмитриевич;[Место защиты: Российский научный центр рентгенорадиологии Министерства здравоохранения Российской Федерации].- Москва, 2016.- 133 с.
13. Bezjak A, Temin S, Franlin G, et al. Deinitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer. American Society of Clinical Oncology. Canceratlas.cancer.org Copyright © 2014 The American Cancer Society, Inc
14. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96.
15. Chen H, Loule A. Stereotactic ablative radiotherapy and surgery: Two gold standard for early-stage non-small cell lung cancer? Annals of Translational Medicine. 2015;3(9):113-116
16. Clinical Practice Guideline Endorsement of the American Society for Radiation
17. Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US), 2013 Apr 5—Identifier NCT00840749. Randomized Study to compare CyberKnife to Surgical resection in stage I Non-small cell lung cancer (STARS) 2209 Feb 7 (Edited 2015 Apr 13)
18. Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US) 2015 jun 2 –Identifier NCT00687986. Trial of Either surgery or Stereotactic Radiotherapy for early Stage (IA) Lung Cancer (ROSEL): 2008.
19. Demaria S, Fomenti S. Can abscopal efects of local radiotherapy be predicted by modeling T cell traicking? Journal for ImmunoTherapy of Cancer. 2016;4:29-31
20. 1. Deterbeck F, Bofa D, Kim A, et al. The eighth edition lung cancer stage classiication. Chest. 2017;151(1):193-203
21. Diwanji T, Mohindra P, Vyhuis M, et al. Advances in radiotherapy techniques an delivery for non-small cell lung cancer: Beneits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Translational Lung Cancer Research. 2017;6(2):131-147
22. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.
23. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
24. Fernandez IP, Quero A, Cueto Ladron de Guevara A: Tratamiento quirurgico del CNCP metapas I y II. Revista Española de Patología Torácica. 2017;21(2, Suppl I):79-84
25. Hopmans W, Damman OC, Senan S, Hartemink KJ, Smit EF, Timmermans DR. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer. 2015;15:959.
26. Janes S, Takrar R, Singer J, et al. London Cancer. Radiotherapy Guideline for Treatment of Lung Cancer. London Cancer, North and East. June 2014;10:304-337
27. Longo D. Recent developments in radiotherapy. The New England Journal of Medicine. 2017;14:1065-1075
28. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114:138–47.
29. Macbeth F, Abrat R, Cho K, et al. Lung cancer management in limited resource settings: Guideline for appropriate good care. IAEA clinical Guideline. Radiotherapy and Oncology. 2007;82:123-131
30. Mahmood S, Bilal H, Faivre-Finn C, et al. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small cell lung cancer? Interactive Cardiovascular and Thoracic Surgery. 2013;17(5):845-853
31. Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol. 2016;2:359–67.
32. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—Non-small-cell lung cancer. Fort Washington, org/professionals/physician_gls/pdf/nscl.pdf [Accessed: 21 September 2017]
33. Oncology Evidence-based Clinical Practice Guideline. Journal of Clinical Oncology. 2015;33(18):2100-2105
34. Palma D, Visser D, Lagenward FJ, et al. Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and Oncology. 2011;101(2):2404
35. Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.
36. Siegel R, Miller K, Jemal A. Cancer statistics 2017. Cancer Journal for Clinicians. 2017;67:7-30
37. Van der Voort VZ, Prevost JB, Hogerman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome. Radiation Oncology. 2009;91:296-300
38. Yu J, Soulos P, Crammer L, et al. Comparative efectiveness of surgery and radiosurgery for stage I none-small cell lung cancer. Cancer. 2015;121:2341-2349
39. Monjazeb A, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small cell lung cancer. Journal of Thoracic Oncology. 2015;10:1685-1693
40. Zenng X, Schipper M, Kidwel K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2014;9083:603-611
41. Valle LE, Jagsi R, Robiak SN, Zornosa C, et al. Variation in definitive therapy for localized non-small cell lung cancer among National Comprehensive Cancer Network Institution. International Journal of Radiation Oncology, Biology, Physics. 2016; 94(2):360-367
42. Lagenward FJ, Veretegen NE, Haasbeek CJ, et al. Outcome of stereotactic ablative radiotherapy in patients with potentially operative stage I non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 20128;3(1):384-353
43. Cancer Council Australia Lung Cancer. Guideline Working Party. Clinical Practice Guideline for the treatment of lung cáncer. Sydney: Cancer Council Australia; 2015:874
44. Villar Alvarez F, Muguruza Trueba I, Belda Sanchis J, et al. Recomendaciones de SEPAR de diagnostico y tratamiento del cáncer de pulmón de células no pequeñas, Archivos de Bronconeumologнa. 2016;52(Supl 1):2-62
45. Garrido P, Olmedo MªE. State of the art of radiotherapy. Transl Lung Cancer Res. 2013;2(3):189-199
46. Slotman BJ, Lagerward FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncologica. 2006;45(7):966-972
47. Gore EM, Bae K, Wing SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Primary analysis of radiation therapy oncology group study RTOG 0214. Journal of Clinical Oncology. 2011;29(3):272-278
48. Speruto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology. 2012;30(4):419-425
49. Gaspar L, Scott C, Rotman M, et al. Recursive portioning analysis (RPA) of prognosis factors in three radiation therapy oncology group (RTOG) brain metastases trials. International Journal of Radiation Oncology, Biology, Physics. 1997;37(4):745-751
50. Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688-697.
51. Bradley DJ, Paulus R, Komaki R, Masters GA, Forster K, Schild SE et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(Suppl.):abstr.7501.
52. Arya Amini, Steven H Lin,Caimiao Wei, Pamela Allen,James D Cox and Ritsuko Komaki. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiation Oncology20127:33
Anikeeva O.Ju. Sravnenie stereotaksicheskih metodik obluchenija nachal'nyh stadij nemelkokletochnogo raka legkogo u pozhilyh pacientov/ O.Ju. Anikeeva, K.S. Tevs, O.A. Pashkovskaja, E.A. Samojlova// Rossijskij onkologicheskij zhurnal.2014. No1–S.13–19. (In Russ)
Arsen'ev A.I., Kanaev S.V., Novikov S.N., Barchuk A.A., Antipov F.E. Sovremennye tendencii ispol'zovanija luchevoj terapii v lechenii mestnorasprostranennyh (IIIA / N2 stadija) i rannih form (I–II stadija) nemelkokletochnogo raka legkogo, ili rol' luchevoj terapii v lechenii nemelkokletochnogo raka legkogo na sovremennom jetape. Zlokachestvennye opuholi. 2017;(3s1):26-34. (In Russ)
Val'kov M. Ju., Skripach Ju. V., Solov'eva E. P. s soavt. Metody lechenija i ishody pri mestno-rasprostranennom rake legkogo III stadii: populjacionnyj analiz.//Vestnik RNCRR. -2014. -№ 9. -str. 9. (In Russ)
Gogolin D., Gulidov I., Ragulin Ju. Luchevaja terapija v lechenii nemelkokletochnogo raka legkogo Vrach. 2016.-N 2.-S.46-48 (In Russ)
Klimanov M.Ju., Sivak L.A., Tarasenko T.E., Askol'skij A.V., Majdanevich N.N., Ljal'kin S.A., Verevkina N.O. Sovremennye podhody k lecheniju pacientov s neoperabel'nym nemelkokletochnym rakom legkogo// Nacional'nyj institut raka, Kiev (In Russ)
Luchevaja terapija zabolevanij organov grudnoj kletki. Luchevaja diagnostika organov grudnoj kletki/ T. R.Alekseeva, A.I.Shehter, V.N.Trojan, O.Ju.Anikeeva// Nacional'noe rukovodstvo.–M.: GJeOTAR-Media, 2014. –Gl. 2 (In Russ)
AnikeevaO.Ju. Algoritm vybora metodiki obluchenija u bol'nyh rakom legkogo s serdechno-sosudistoj patologiej/O.Ju. Anikeeva, E.V. Kizhaev, P. V. Filatov, O.A. Pashkovskaja//Rossijskij jelektronnyj zhurnal luchevoj diagnostiki (REJR). –2015.–T. 5. –No 4.S 74-82 (In Russ)
Martynova N.I. , Vorob'ev N.A. , Mihajlov A.V. , Smirnova E.V. , Gucalo Ju.V. Primenenie stereotaksicheskoj luchevoj terapii u pacientov s pervichnymi i metastaticheskimi opuholjami legkih. Reguljarnye vypuski «RMZh» №16 ot 07.09.2017 str. 1169-1172 (In Russ)
Solov'eva E.P.Faktory jeffektivnosti lechenija neoperabel'nogo nemelkokletochnogo raka legkogo III stadii// Sibirskij onkologicheskij zhurnal.2016.-№4.-S.39-44 (In Russ)
Solodkij V.A., Sotnikov V.M., Pan'shin G.A., Trocenko S.D., Harchenko V.P., Chhikvadze V.D., Nudnov N.V., Morgunov A.A. Rol' sovremennyh tehnologij posleoperacionnoj luchevoj terapii v kombinirovannom lechenii nemelkokletochnogo raka legkogo. Zlokachestvennye opuholi. 2017.-№3. S. 28-32 (In Russ)
Trocenko S. D., Solodkij V. A., Sotnikov V. M. i dr. Rezul'taty hirurgicheskogo i kombinirovannogo lechenija nemelkokletochnogo raka legkogo s posleoperacionnoj luchevoj terapiej v rezhime gipofrakcionirovanija. Obshhaja i bolezn'-specifichnaja vyzhivaemost'.//Voprosy onkologii. -2015. -T. 61. -№ 1. -S. 71-76 (In Russ)
Trocenko Sergej Dmitrievich. Posleoperacionnaja luchevaja terapija nemelkokletochnogo raka legkogo v rezhime srednego frakcionirovanija: dissertacija ... kandidata Medicinskih nauk: 14.01.13 / Trocenko Sergej Dmitrievich;[Mesto zashhity: Rossijskij nauchnyj centr rentgenoradiologii Ministerstva zdravoohranenija Rossijskoj Federacii].- Moskva, 2016.- 133 s. (In Russ)
Bezjak A, Temin S, Franlin G, et al. Deinitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer. American Society of Clinical Oncology. Canceratlas.cancer.org Copyright © 2014 The American Cancer Society, Inc
Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96.
Chen H, Loule A. Stereotactic ablative radiotherapy and surgery: Two gold standard for early-stage non-small cell lung cancer? Annals of Translational Medicine. 2015;3(9):113-116
Clinical Practice Guideline Endorsement of the American Society for Radiation
Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US), 2013 Apr 5—Identifier NCT00840749. Randomized Study to compare CyberKnife to Surgical resection in stage I Non-small cell lung cancer (STARS) 2209 Feb 7 (Edited 2015 Apr 13)
Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US) 2015 jun 2 –Identifier NCT00687986. Trial of Either surgery or Stereotactic Radiotherapy for early Stage (IA) Lung Cancer (ROSEL): 2008.
Demaria S, Fomenti S. Can abscopal efects of local radiotherapy be predicted by modeling T cell traicking? Journal for ImmunoTherapy of Cancer. 2016;4:29-31
1. Deterbeck F, Bofa D, Kim A, et al. The eighth edition lung cancer stage classiication. Chest. 2017;151(1):193-203
Diwanji T, Mohindra P, Vyhuis M, et al. Advances in radiotherapy techniques an delivery for non-small cell lung cancer: Beneits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Translational Lung Cancer Research. 2017;6(2):131-147
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Fernandez IP, Quero A, Cueto Ladron de Guevara A: Tratamiento quirurgico del CNCP metapas I y II. Revista Española de Patología Torácica. 2017;21(2, Suppl I):79-84
Hopmans W, Damman OC, Senan S, Hartemink KJ, Smit EF, Timmermans DR. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer. 2015;15:959.
Janes S, Takrar R, Singer J, et al. London Cancer. Radiotherapy Guideline for Treatment of Lung Cancer. London Cancer, North and East. June 2014;10:304-337
Longo D. Recent developments in radiotherapy. The New England Journal of Medicine. 2017;14:1065-1075
Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114:138–47.
Macbeth F, Abrat R, Cho K, et al. Lung cancer management in limited resource settings: Guideline for appropriate good care. IAEA clinical Guideline. Radiotherapy and Oncology. 2007;82:123-131
Mahmood S, Bilal H, Faivre-Finn C, et al. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small cell lung cancer? Interactive Cardiovascular and Thoracic Surgery. 2013;17(5):845-853
Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol. 2016;2:359–67.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—Non-small-cell lung cancer. Fort Washington, org/professionals/physician_gls/pdf/nscl.pdf [Accessed: 21 September 2017]
Oncology Evidence-based Clinical Practice Guideline. Journal of Clinical Oncology. 2015;33(18):2100-2105
Palma D, Visser D, Lagenward FJ, et al. Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and Oncology. 2011;101(2):2404
Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.
Siegel R, Miller K, Jemal A. Cancer statistics 2017. Cancer Journal for Clinicians. 2017;67:7-30
Van der Voort VZ, Prevost JB, Hogerman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome. Radiation Oncology. 2009;91:296-300
Yu J, Soulos P, Crammer L, et al. Comparative efectiveness of surgery and radiosurgery for stage I none-small cell lung cancer. Cancer. 2015;121:2341-2349
Monjazeb A, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small cell lung cancer. Journal of Thoracic Oncology. 2015;10:1685-1693
Zenng X, Schipper M, Kidwel K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2014;9083:603-611
Valle LE, Jagsi R, Robiak SN, Zornosa C, et al. Variation in definitive therapy for localized non-small cell lung cancer among National Comprehensive Cancer Network Institution. International Journal of Radiation Oncology, Biology, Physics. 2016; 94(2):360-367
Lagenward FJ, Veretegen NE, Haasbeek CJ, et al. Outcome of stereotactic ablative radiotherapy in patients with potentially operative stage I non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 20128;3(1):384-353
Cancer Council Australia Lung Cancer. Guideline Working Party. Clinical Practice Guideline for the treatment of lung cáncer. Sydney: Cancer Council Australia; 2015:874
Villar Alvarez F, Muguruza Trueba I, Belda Sanchis J, et al. Recomendaciones de SEPAR de diagnostico y tratamiento del cáncer de pulmón de células no pequeñas, Archivos de Bronconeumologнa. 2016;52(Supl 1):2-62
Garrido P, Olmedo MªE. State of the art of radiotherapy. Transl Lung Cancer Res. 2013;2(3):189-199
Slotman BJ, Lagerward FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncologica. 2006;45(7):966-972
Gore EM, Bae K, Wing SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Primary analysis of radiation therapy oncology group study RTOG 0214. Journal of Clinical Oncology. 2011;29(3):272-278
Speruto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology. 2012;30(4):419-425
Gaspar L, Scott C, Rotman M, et al. Recursive portioning analysis (RPA) of prognosis factors in three radiation therapy oncology group (RTOG) brain metastases trials. International Journal of Radiation Oncology, Biology, Physics. 1997;37(4):745-751
Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688-697.
Bradley DJ, Paulus R, Komaki R, Masters GA, Forster K, Schild SE et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(Suppl.):abstr.7501.
Arya Amini, Steven H Lin,Caimiao Wei, Pamela Allen,James D Cox and Ritsuko Komaki. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiation Oncology20127:33
2. Арсеньев А.И., Канаев С.В., Новиков С.Н., Барчук А.А., Антипов Ф.Е. Современные тенденции использования лучевой терапии в лечении местнораспространенных (IIIA / N2 стадия) и ранних форм (I–II стадия) немелкоклеточного рака легкого, или роль лучевой терапии в лечении немелкоклеточного рака легкого на современном этапе. Злокачественные опухоли. 2017;(3s1):26-34.
3. Вальков М. Ю., Скрипач Ю. В., Соловьева Е. П. с соавт. Методы лечения и исходы при местно-распространенном раке легкого III стадии: популяционный анализ.//Вестник РНЦРР. -2014. -№ 9. -стр. 9.
4. Гоголин Д., Гулидов И., Рагулин Ю. Лучевая терапия в лечении немелкоклеточного рака легкого Врач. 2016.-N 2.-С.46-48
5. Климанов М.Ю., Сивак Л.А., Тарасенко Т.E., Аскольский А.В., Майданевич Н.Н., Лялькин С.А., Веревкина Н.О. Современные подходы к лечению пациентов с неоперабельным немелкоклеточным раком легкого// Национальный институт рака, Киев
6. Лучевая терапия заболеваний органов грудной клетки. Лучевая диагностика органов грудной клетки/ Т. Р.Алексеева, А.И.Шехтер, В.Н.Троян, О.Ю.Аникеева// Национальное руководство.–М.: ГЭОТАР-Медиа, 2014. –Гл. 2
7. АникееваО.Ю. Алгоритм выбора методики облучения у больных раком легкого с сердечно-сосудистой патологией/О.Ю. Аникеева, Е.В. Кижаев, П. В. Филатов, О.А. Пашковская//Российский электронный журнал лучевой диагностики (REJR). –2015.–Т. 5. –No 4.С 74-82
8. Мартынова Н.И. , Воробьев Н.А. , Михайлов А.В. , Смирнова Е.В. , Гуцало Ю.В. Применение стереотаксической лучевой терапии у пациентов с первичными и метастатическими опухолями легких. Регулярные выпуски «РМЖ» №16 от 07.09.2017 стр. 1169-1172
9. Соловьева Е.П.Факторы эффективности лечения неоперабельного немелкоклеточного рака легкого III стадии// Сибирский онкологический журнал.2016.-№4.-С.39-44
10. Солодкий В.А., Сотников В.М., Паньшин Г.А., Троценко С.Д., Харченко В.П., Чхиквадзе В.Д., Нуднов Н.В., Моргунов А.А. Роль современных технологий послеоперационной лучевой терапии в комбинированном лечении немелкоклеточного рака легкого. Злокачественные опухоли. 2017.-№3. С. 28-32
11. Троценко С. Д., Солодкий В. А., Сотников В. М. и др. Результаты хирургического и комбинированного лечения немелкоклеточного рака легкого с послеоперационной лучевой терапией в режиме гипофракционирования. Общая и болезнь-специфичная выживаемость.//Вопросы онкологии. -2015. -Т. 61. -№ 1. -С. 71-76
12. Троценко Сергей Дмитриевич. Послеоперационная лучевая терапия немелкоклеточного рака легкого в режиме среднего фракционирования: диссертация ... кандидата Медицинских наук: 14.01.13 / Троценко Сергей Дмитриевич;[Место защиты: Российский научный центр рентгенорадиологии Министерства здравоохранения Российской Федерации].- Москва, 2016.- 133 с.
13. Bezjak A, Temin S, Franlin G, et al. Deinitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer. American Society of Clinical Oncology. Canceratlas.cancer.org Copyright © 2014 The American Cancer Society, Inc
14. Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96.
15. Chen H, Loule A. Stereotactic ablative radiotherapy and surgery: Two gold standard for early-stage non-small cell lung cancer? Annals of Translational Medicine. 2015;3(9):113-116
16. Clinical Practice Guideline Endorsement of the American Society for Radiation
17. Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US), 2013 Apr 5—Identifier NCT00840749. Randomized Study to compare CyberKnife to Surgical resection in stage I Non-small cell lung cancer (STARS) 2209 Feb 7 (Edited 2015 Apr 13)
18. Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US) 2015 jun 2 –Identifier NCT00687986. Trial of Either surgery or Stereotactic Radiotherapy for early Stage (IA) Lung Cancer (ROSEL): 2008.
19. Demaria S, Fomenti S. Can abscopal efects of local radiotherapy be predicted by modeling T cell traicking? Journal for ImmunoTherapy of Cancer. 2016;4:29-31
20. 1. Deterbeck F, Bofa D, Kim A, et al. The eighth edition lung cancer stage classiication. Chest. 2017;151(1):193-203
21. Diwanji T, Mohindra P, Vyhuis M, et al. Advances in radiotherapy techniques an delivery for non-small cell lung cancer: Beneits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Translational Lung Cancer Research. 2017;6(2):131-147
22. Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.
23. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
24. Fernandez IP, Quero A, Cueto Ladron de Guevara A: Tratamiento quirurgico del CNCP metapas I y II. Revista Española de Patología Torácica. 2017;21(2, Suppl I):79-84
25. Hopmans W, Damman OC, Senan S, Hartemink KJ, Smit EF, Timmermans DR. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer. 2015;15:959.
26. Janes S, Takrar R, Singer J, et al. London Cancer. Radiotherapy Guideline for Treatment of Lung Cancer. London Cancer, North and East. June 2014;10:304-337
27. Longo D. Recent developments in radiotherapy. The New England Journal of Medicine. 2017;14:1065-1075
28. Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114:138–47.
29. Macbeth F, Abrat R, Cho K, et al. Lung cancer management in limited resource settings: Guideline for appropriate good care. IAEA clinical Guideline. Radiotherapy and Oncology. 2007;82:123-131
30. Mahmood S, Bilal H, Faivre-Finn C, et al. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small cell lung cancer? Interactive Cardiovascular and Thoracic Surgery. 2013;17(5):845-853
31. Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol. 2016;2:359–67.
32. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—Non-small-cell lung cancer. Fort Washington, org/professionals/physician_gls/pdf/nscl.pdf [Accessed: 21 September 2017]
33. Oncology Evidence-based Clinical Practice Guideline. Journal of Clinical Oncology. 2015;33(18):2100-2105
34. Palma D, Visser D, Lagenward FJ, et al. Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and Oncology. 2011;101(2):2404
35. Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.
36. Siegel R, Miller K, Jemal A. Cancer statistics 2017. Cancer Journal for Clinicians. 2017;67:7-30
37. Van der Voort VZ, Prevost JB, Hogerman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome. Radiation Oncology. 2009;91:296-300
38. Yu J, Soulos P, Crammer L, et al. Comparative efectiveness of surgery and radiosurgery for stage I none-small cell lung cancer. Cancer. 2015;121:2341-2349
39. Monjazeb A, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small cell lung cancer. Journal of Thoracic Oncology. 2015;10:1685-1693
40. Zenng X, Schipper M, Kidwel K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2014;9083:603-611
41. Valle LE, Jagsi R, Robiak SN, Zornosa C, et al. Variation in definitive therapy for localized non-small cell lung cancer among National Comprehensive Cancer Network Institution. International Journal of Radiation Oncology, Biology, Physics. 2016; 94(2):360-367
42. Lagenward FJ, Veretegen NE, Haasbeek CJ, et al. Outcome of stereotactic ablative radiotherapy in patients with potentially operative stage I non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 20128;3(1):384-353
43. Cancer Council Australia Lung Cancer. Guideline Working Party. Clinical Practice Guideline for the treatment of lung cáncer. Sydney: Cancer Council Australia; 2015:874
44. Villar Alvarez F, Muguruza Trueba I, Belda Sanchis J, et al. Recomendaciones de SEPAR de diagnostico y tratamiento del cáncer de pulmón de células no pequeñas, Archivos de Bronconeumologнa. 2016;52(Supl 1):2-62
45. Garrido P, Olmedo MªE. State of the art of radiotherapy. Transl Lung Cancer Res. 2013;2(3):189-199
46. Slotman BJ, Lagerward FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncologica. 2006;45(7):966-972
47. Gore EM, Bae K, Wing SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Primary analysis of radiation therapy oncology group study RTOG 0214. Journal of Clinical Oncology. 2011;29(3):272-278
48. Speruto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology. 2012;30(4):419-425
49. Gaspar L, Scott C, Rotman M, et al. Recursive portioning analysis (RPA) of prognosis factors in three radiation therapy oncology group (RTOG) brain metastases trials. International Journal of Radiation Oncology, Biology, Physics. 1997;37(4):745-751
50. Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688-697.
51. Bradley DJ, Paulus R, Komaki R, Masters GA, Forster K, Schild SE et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(Suppl.):abstr.7501.
52. Arya Amini, Steven H Lin,Caimiao Wei, Pamela Allen,James D Cox and Ritsuko Komaki. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiation Oncology20127:33
Anikeeva O.Ju. Sravnenie stereotaksicheskih metodik obluchenija nachal'nyh stadij nemelkokletochnogo raka legkogo u pozhilyh pacientov/ O.Ju. Anikeeva, K.S. Tevs, O.A. Pashkovskaja, E.A. Samojlova// Rossijskij onkologicheskij zhurnal.2014. No1–S.13–19. (In Russ)
Arsen'ev A.I., Kanaev S.V., Novikov S.N., Barchuk A.A., Antipov F.E. Sovremennye tendencii ispol'zovanija luchevoj terapii v lechenii mestnorasprostranennyh (IIIA / N2 stadija) i rannih form (I–II stadija) nemelkokletochnogo raka legkogo, ili rol' luchevoj terapii v lechenii nemelkokletochnogo raka legkogo na sovremennom jetape. Zlokachestvennye opuholi. 2017;(3s1):26-34. (In Russ)
Val'kov M. Ju., Skripach Ju. V., Solov'eva E. P. s soavt. Metody lechenija i ishody pri mestno-rasprostranennom rake legkogo III stadii: populjacionnyj analiz.//Vestnik RNCRR. -2014. -№ 9. -str. 9. (In Russ)
Gogolin D., Gulidov I., Ragulin Ju. Luchevaja terapija v lechenii nemelkokletochnogo raka legkogo Vrach. 2016.-N 2.-S.46-48 (In Russ)
Klimanov M.Ju., Sivak L.A., Tarasenko T.E., Askol'skij A.V., Majdanevich N.N., Ljal'kin S.A., Verevkina N.O. Sovremennye podhody k lecheniju pacientov s neoperabel'nym nemelkokletochnym rakom legkogo// Nacional'nyj institut raka, Kiev (In Russ)
Luchevaja terapija zabolevanij organov grudnoj kletki. Luchevaja diagnostika organov grudnoj kletki/ T. R.Alekseeva, A.I.Shehter, V.N.Trojan, O.Ju.Anikeeva// Nacional'noe rukovodstvo.–M.: GJeOTAR-Media, 2014. –Gl. 2 (In Russ)
AnikeevaO.Ju. Algoritm vybora metodiki obluchenija u bol'nyh rakom legkogo s serdechno-sosudistoj patologiej/O.Ju. Anikeeva, E.V. Kizhaev, P. V. Filatov, O.A. Pashkovskaja//Rossijskij jelektronnyj zhurnal luchevoj diagnostiki (REJR). –2015.–T. 5. –No 4.S 74-82 (In Russ)
Martynova N.I. , Vorob'ev N.A. , Mihajlov A.V. , Smirnova E.V. , Gucalo Ju.V. Primenenie stereotaksicheskoj luchevoj terapii u pacientov s pervichnymi i metastaticheskimi opuholjami legkih. Reguljarnye vypuski «RMZh» №16 ot 07.09.2017 str. 1169-1172 (In Russ)
Solov'eva E.P.Faktory jeffektivnosti lechenija neoperabel'nogo nemelkokletochnogo raka legkogo III stadii// Sibirskij onkologicheskij zhurnal.2016.-№4.-S.39-44 (In Russ)
Solodkij V.A., Sotnikov V.M., Pan'shin G.A., Trocenko S.D., Harchenko V.P., Chhikvadze V.D., Nudnov N.V., Morgunov A.A. Rol' sovremennyh tehnologij posleoperacionnoj luchevoj terapii v kombinirovannom lechenii nemelkokletochnogo raka legkogo. Zlokachestvennye opuholi. 2017.-№3. S. 28-32 (In Russ)
Trocenko S. D., Solodkij V. A., Sotnikov V. M. i dr. Rezul'taty hirurgicheskogo i kombinirovannogo lechenija nemelkokletochnogo raka legkogo s posleoperacionnoj luchevoj terapiej v rezhime gipofrakcionirovanija. Obshhaja i bolezn'-specifichnaja vyzhivaemost'.//Voprosy onkologii. -2015. -T. 61. -№ 1. -S. 71-76 (In Russ)
Trocenko Sergej Dmitrievich. Posleoperacionnaja luchevaja terapija nemelkokletochnogo raka legkogo v rezhime srednego frakcionirovanija: dissertacija ... kandidata Medicinskih nauk: 14.01.13 / Trocenko Sergej Dmitrievich;[Mesto zashhity: Rossijskij nauchnyj centr rentgenoradiologii Ministerstva zdravoohranenija Rossijskoj Federacii].- Moskva, 2016.- 133 s. (In Russ)
Bezjak A, Temin S, Franlin G, et al. Deinitive and adjuvant radiotherapy in locally advanced non-small cell lung cancer. American Society of Clinical Oncology. Canceratlas.cancer.org Copyright © 2014 The American Cancer Society, Inc
Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, et al. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006;65:1087–96.
Chen H, Loule A. Stereotactic ablative radiotherapy and surgery: Two gold standard for early-stage non-small cell lung cancer? Annals of Translational Medicine. 2015;3(9):113-116
Clinical Practice Guideline Endorsement of the American Society for Radiation
Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US), 2013 Apr 5—Identifier NCT00840749. Randomized Study to compare CyberKnife to Surgical resection in stage I Non-small cell lung cancer (STARS) 2209 Feb 7 (Edited 2015 Apr 13)
Clinical/Trials.gov (Internet). Bethesda (MD): National Library of medicine (US) 2015 jun 2 –Identifier NCT00687986. Trial of Either surgery or Stereotactic Radiotherapy for early Stage (IA) Lung Cancer (ROSEL): 2008.
Demaria S, Fomenti S. Can abscopal efects of local radiotherapy be predicted by modeling T cell traicking? Journal for ImmunoTherapy of Cancer. 2016;4:29-31
1. Deterbeck F, Bofa D, Kim A, et al. The eighth edition lung cancer stage classiication. Chest. 2017;151(1):193-203
Diwanji T, Mohindra P, Vyhuis M, et al. Advances in radiotherapy techniques an delivery for non-small cell lung cancer: Beneits of intensity-modulated radiation therapy, proton therapy, and stereotactic body radiation therapy. Translational Lung Cancer Research. 2017;6(2):131-147
Eberhardt WE, De Ruysscher D, Weder W, Le Péchoux C, De Leyn P, Hoffmann H, et al. 2nd ESMO consensus conference in lung cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015;26:1573–88.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Fernandez IP, Quero A, Cueto Ladron de Guevara A: Tratamiento quirurgico del CNCP metapas I y II. Revista Española de Patología Torácica. 2017;21(2, Suppl I):79-84
Hopmans W, Damman OC, Senan S, Hartemink KJ, Smit EF, Timmermans DR. A patient perspective on shared decision making in stage I non-small cell lung cancer: a mixed methods study. BMC Cancer. 2015;15:959.
Janes S, Takrar R, Singer J, et al. London Cancer. Radiotherapy Guideline for Treatment of Lung Cancer. London Cancer, North and East. June 2014;10:304-337
Longo D. Recent developments in radiotherapy. The New England Journal of Medicine. 2017;14:1065-1075
Louie AV, Palma DA, Dahele M, Rodrigues GB, Senan S. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015;114:138–47.
Macbeth F, Abrat R, Cho K, et al. Lung cancer management in limited resource settings: Guideline for appropriate good care. IAEA clinical Guideline. Radiotherapy and Oncology. 2007;82:123-131
Mahmood S, Bilal H, Faivre-Finn C, et al. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small cell lung cancer? Interactive Cardiovascular and Thoracic Surgery. 2013;17(5):845-853
Movsas B, Hu C, Sloan J, Bradley J, Komaki R, Masters G, et al. Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial. JAMA Oncol. 2016;2:359–67.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology—Non-small-cell lung cancer. Fort Washington, org/professionals/physician_gls/pdf/nscl.pdf [Accessed: 21 September 2017]
Oncology Evidence-based Clinical Practice Guideline. Journal of Clinical Oncology. 2015;33(18):2100-2105
Palma D, Visser D, Lagenward FJ, et al. Treatment of stage I NSCLC in elderly patients: A population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiotherapy and Oncology. 2011;101(2):2404
Ricardi U, Frezza G, Filippi AR, et al. Stereotactic ablative radiotherapy for stage I hisologically proven non-small cell lung cancer: an Italian multicenter observational study. Lung Cancer. 2014;84:248–53.
Siegel R, Miller K, Jemal A. Cancer statistics 2017. Cancer Journal for Clinicians. 2017;67:7-30
Van der Voort VZ, Prevost JB, Hogerman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: Clinical outcome. Radiation Oncology. 2009;91:296-300
Yu J, Soulos P, Crammer L, et al. Comparative efectiveness of surgery and radiosurgery for stage I none-small cell lung cancer. Cancer. 2015;121:2341-2349
Monjazeb A, Kelly K. Clinical trials integrating immunotherapy and radiation for non-small cell lung cancer. Journal of Thoracic Oncology. 2015;10:1685-1693
Zenng X, Schipper M, Kidwel K, et al. Survival outcome after stereotactic body radiation therapy and surgery for stage I non-small cell lung cancer: A meta-analysis. International Journal of Radiation Oncology, Biology, Physics. 2014;9083:603-611
Valle LE, Jagsi R, Robiak SN, Zornosa C, et al. Variation in definitive therapy for localized non-small cell lung cancer among National Comprehensive Cancer Network Institution. International Journal of Radiation Oncology, Biology, Physics. 2016; 94(2):360-367
Lagenward FJ, Veretegen NE, Haasbeek CJ, et al. Outcome of stereotactic ablative radiotherapy in patients with potentially operative stage I non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 20128;3(1):384-353
Cancer Council Australia Lung Cancer. Guideline Working Party. Clinical Practice Guideline for the treatment of lung cáncer. Sydney: Cancer Council Australia; 2015:874
Villar Alvarez F, Muguruza Trueba I, Belda Sanchis J, et al. Recomendaciones de SEPAR de diagnostico y tratamiento del cáncer de pulmón de células no pequeñas, Archivos de Bronconeumologнa. 2016;52(Supl 1):2-62
Garrido P, Olmedo MªE. State of the art of radiotherapy. Transl Lung Cancer Res. 2013;2(3):189-199
Slotman BJ, Lagerward FJ, Senan S. 4D imaging for target definition in stereotactic radiotherapy for lung cancer. Acta Oncologica. 2006;45(7):966-972
Gore EM, Bae K, Wing SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer. Primary analysis of radiation therapy oncology group study RTOG 0214. Journal of Clinical Oncology. 2011;29(3):272-278
Speruto PW, Kased N, Roberge D, et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. Journal of Clinical Oncology. 2012;30(4):419-425
Gaspar L, Scott C, Rotman M, et al. Recursive portioning analysis (RPA) of prognosis factors in three radiation therapy oncology group (RTOG) brain metastases trials. International Journal of Radiation Oncology, Biology, Physics. 1997;37(4):745-751
Roswit B, Patno ME, Rapp R. The survival of patients with inoperable lung cancer: a large randomized study of radiation therapy verses placebo. Am J Roentgenol. 1968;90:688-697.
Bradley DJ, Paulus R, Komaki R, Masters GA, Forster K, Schild SE et al. A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer. Results on radiation dose in RTOG 0617. J Clin Oncol. 2013;31(Suppl.):abstr.7501.
Arya Amini, Steven H Lin,Caimiao Wei, Pamela Allen,James D Cox and Ritsuko Komaki. Accelerated hypofractionated radiation therapy compared to conventionally fractionated radiation therapy for the treatment of inoperable non-small cell lung cancer. Radiation Oncology20127:33
Опубликована
2020-06-02
Как цитировать
СЕМИКОЗ, Н Г et al.
Лучевая терапия в комбинированном лечении немелкоклеточного рака легкого. Объемы облучения, фракционирования дозы.
Новообразование, [S.l.], v. 12, n. 2, p. 53-62, июня 2020.
ISSN 2521-117X.
Доступно на: <http://donetsk-onco.com/neoplasm/index.php/Neoplasm/article/view/321>. Дата доступа: 20 апр. 2024
doi: https://doi.org/10.26435/neoplasm.v12i2.321.
Раздел
Оригинальные статьи
